ABSTRACT
Anti-erythropoietin antibodies usually cross-react with all kinds of recombinant erythropoietins; therefore, erythropoiesis-stimulating agent (ESA)-induced pure red-cell aplasia (PRCA) is not rescued by different ESAs. Here, we present a case of ESA-induced PRCA in a 36-yr-old woman with chronic kidney disease, whose anemic condition improved following reintroduction of darbepoetin-alpha. The patient developed progressive, severe anemia after the use of erythropoietin-alpha. As the anemia did not improve after the administration of either other erythropoietin-alpha products or erythropoietin-beta, all ESAs were discontinued. Oxymetholone therapy failed to improve the transfusion-dependent anemia and a rechallenge with ESAs continuously failed to obtain a sustained response. However, her anemia improved following reintroduction of darbepoetin-alpha at 3 yr after the initial diagnosis. Interestingly, anti-erythropoietin antibodies were still detectable, although their concentration was too low for titration. In conclusion, darbepoetin-alpha can improve ESA-induced PRCA when the anti-erythropoietin antibody titer declines and its neutralizing capacity is lost.
Subject(s)
Adult , Female , Humans , Anemia/drug therapy , Antibodies/blood , Bone Marrow Cells/pathology , Drug Hypersensitivity/immunology , Erythropoietin/analogs & derivatives , Erythropoietin/adverse effects , Glomerulonephritis, IGA/complications , Hematinics/adverse effects , Kidney Failure, Chronic/complications , Oxymetholone/therapeutic use , Red-Cell Aplasia, Pure/chemically inducedABSTRACT
Ticlopidine inhibits platelet aggregation and provides beneficial secondary prevention of cerebrovascular and coronary artery disease. Frequently reported adverse effects of ticlopidine include diarrhea, nausea, and rash. However, to our knowledge, there are only a few published reports of the simultaneous occurrence of cholestatic hepatitis and pure red cell aplasia. Here we report a patient with simultaneous severe cholestatic hepatitis and pure red cell aplasia associated with ticlopidine. Although these adverse effects are rare, periodic hematological and liver function tests are recommended after starting ticlopidine.
Subject(s)
Female , Humans , Middle Aged , Acute Disease , Cholestasis/chemically induced , Chemical and Drug Induced Liver Injury/diagnosis , Liver Function Tests , Platelet Aggregation Inhibitors/adverse effects , Red-Cell Aplasia, Pure/chemically induced , Ticlopidine/adverse effectsABSTRACT
Pure red cell aplasia is an uncommon complication of diphenylhydantoin therapy. It has not been reported in Indian literature. Awareness of the entity helps in establishing the cause of anaemia in these patients and alerts the physicians to the need of comprehensive haematological monitoring in these patients. A case of 58-year-old male who developed pure red cell aplasia following three months of diphenylhydantoin therapy is reported here.
Subject(s)
Anticonvulsants/adverse effects , Humans , Male , Middle Aged , Phenytoin/adverse effects , Red-Cell Aplasia, Pure/chemically induced , Risk Assessment , Risk FactorsABSTRACT
Therapeutic indications for carbamazepine have grown in recent years and more and more patients are taking this drug for various neurological and psychiatric disorders. Though haematological complications like aplastic anaemia etc., due to carbamazepine therapy are well known pure red cell aplasia is exceedingly rare. A 33 year old man was diagnosed to have pure red cell aplasia with positive Coomb's test following 5 months of carbamazepine therapy. He recovered completely. Carbamazepine induced pure red cell aplasia is a reversible condition if recognised early.